Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas
Open Access
- 3 June 2008
- journal article
- Published by Springer Nature in Breast Cancer Research
- Vol. 10 (3) , R49
Abstract
Introduction: Epidermal growth factor receptor (EGFR) is involved in regulating cell growth in breast carcinomas. Its activated form, phosphorylated EGFR (pEGFR), is correlated with poor prognosis in lung cancer, but it has not yet been fully investigated in breast cancer. The aim of this study was to investigate the expressions of EGFR and pEGFR and their correlation with overall and disease-free survival, clinicopathological parameters and biological markers of invasion and angiogenesis (phosphorylated Akt [pAkt], urokinase plasminogen activator receptor [uPAR], matrix metalloproteinase [MMP]-14, vascular endothelial growth factor receptor [VEGFR]-1/Flt-1). Methods: A three-step immunohistochemical method was applied to paraffin-embedded sections from 154 patients with invasive breast carcinoma in order to detect expressions of the proteins EGFR, pEGFR, oestrogen receptor, progesterone receptor, c-erbB-2, pAkt, VEGFR-1/Flt-1, MMP-14 and uPAR. The results were evaluated statistically using the χ2 test. Overall and disease-free survival distribution curves were assessed using the Kaplan-Meier test and log-rank statistics, followed by Cox proportional hazards regression model. Results: EGFR and pEGFR proteins were immunodetected in the membrane of the malignant cells (11.3% and 35.7%, respectively). EGFR expression was positively correlated with nuclear grade (P = 0.001) and negatively correlated with the hormonal receptor oestrogen receptor (P = 0.005). pEGFR was positively related to the Akt pathway (P = 0.008) and appeared to participate in invasion and metastasis (uPAR, P = 0.049; MMP-14, P = 0.025; VEGFR-1/Flt-1, P = 0.016). Univariate analysis showed that the EGFR/pEGFR phenotype was associated with poor overall survival (P = 0.019), a finding further supported by multivariate analysis (P = 0.013). Conclusion: These data provide evidence that pEGFR expression is related to angiogenesis (via VEGFR-1/Flt-1, MMP-14 and pAkt pathways) and invasiveness (via uPAR, MMP-14 and pAkt pathways) and that the EGFR/pEGFR phenotype is associated with poor patient survival in invasive breast cancer.Keywords
This publication has 38 references indexed in Scilit:
- Prognostic Significance of Overexpression and Phosphorylation of Epidermal Growth Factor Receptor (EGFR) and the Presence of Truncated EGFRvIII in Locoregionally Advanced Breast CancerJournal of Clinical Oncology, 2007
- Rational bases for the development of EGFR inhibitors for cancer treatmentThe International Journal of Biochemistry & Cell Biology, 2007
- High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC)Journal of Clinical Pathology, 2006
- Biological significance of c-erbB family oncogenes in head and neck cancerCancer and Metastasis Reviews, 2005
- HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast CancerClinical Cancer Research, 2004
- The HER receptor family: a rich target for therapeutic developmentInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- Gefitinib in Recurrent Non–Small-Cell Lung Cancer: An IDEAL Trial?Journal of Clinical Oncology, 2003
- Immunohistochemical detection of epidermal growth factor receptor lacks prognostic significance for breast carcinomaJournal of the Society for Gynecologic Investigation, 1995
- Epithelial Differentiation Antigens and Epidermal Growth Factor Receptors in Transitional Cell Bladder Carcinoma: Correlation with PrognosisUrologia Internationalis, 1995
- The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patientsEndocrine Reviews, 1992